Melatonin in Children: What the UK Evidence and Licensing Says

Melatonin for paediatric sleep difficulty sits in a confusing space. In the United States it is sold over the counter as a supplement, often at high doses, often without medical input. In the UK it is a prescription-only medicine, available in specific licensed and off-label forms, with very different regulatory and evidence framing. This piece covers the UK position, what the licensing actually says, what the long-term safety evidence shows, and when melatonin fits as part of paediatric sleep care.

The UK position vs the US

In the UK, melatonin is classified as a medicine. It is prescription-only and is not available over the counter ^[6]. Parents who have read US parenting media sometimes arrive at the pharmacy expecting to buy melatonin gummies; the position is different here.

There are good reasons for the difference. The US supplement market for melatonin has expanded rapidly, with retail products sold at doses well above what the clinical literature supports for paediatric use. Independent quality testing has consistently found wide variation between labelled and actual content. Paediatric melatonin emergency department visits in the US have risen sharply over the last decade, mostly through accidental ingestion. The UK regulatory position is closer to the way melatonin is treated in most of Europe: a medicine, prescribed by a clinician, at doses that match the evidence.

For UK parents, this means the melatonin conversation runs through your GP or paediatrician rather than the pharmacy aisle.

Slenyto specifically

Slenyto is a paediatric prolonged-release melatonin licensed in the UK and across the EU for the treatment of insomnia in children and adolescents aged 2 to 18 with autism spectrum disorder or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient ^[7]. This is one of the few specific paediatric sleep medication licences in the UK and the licensing matters; it represents the clearest formal endorsement of melatonin for any paediatric sleep indication.

The evidence base for Slenyto in autistic children is reasonable. Maras and colleagues' 2018 open-label extension study in the Journal of Child and Adolescent Psychopharmacology followed children for up to 24 months and reported sustained improvement in sleep onset latency and total sleep time, with a reasonable safety profile across that period ^[2]. The trial included careful monitoring of growth, pubertal development and side effects; no signal of concern emerged across the published follow-up.

Practical points for parents whose autistic child may be a candidate:

• Slenyto is the first-line melatonin option in autism. The prescriber will usually want to confirm that sleep hygiene measures have been tried genuinely for several weeks before initiation.
• The starting dose is low and is titrated up if needed; the prescriber will guide this.
• Slenyto is taken 30 to 60 minutes before bedtime.
• It works best as part of a wider sleep approach, not as a standalone fix.

Off-label paediatric melatonin

Most other paediatric melatonin prescribing in the UK is off-label ^{[1, 3]}. The main contexts:

• Children with ADHD and significant sleep onset insomnia. NICE NG87 does not specifically address melatonin in paediatric ADHD; some paediatricians prescribe immediate-release melatonin off-label for this picture, particularly where sleep hygiene has been tried and the child's daytime function is significantly affected. See our paediatric sleep in ADHD piece for the wider behavioural framework.
• Children with other neurodevelopmental conditions (Down syndrome, cerebral palsy, intellectual disability, ADHD without autism).
• Children with delayed sleep phase syndrome.
• Children with jet lag in some cases.
• Children with severe chronic insomnia that has not responded to behavioural intervention.

Off-label use means the medication is being used outside its specific licensed indication; this is legal, common in paediatrics, and supported by the BNFc framework ^[1]. It does mean the conversation with the prescriber is more individual than for licensed indications.

The Bruni 2018 practitioner review in the Journal of Child Psychology and Psychiatry is the most useful single overview of paediatric chronic insomnia treatment in neurodevelopmental disability, including the place of melatonin ^[3].

What the safety evidence does and does not show

The honest position on long-term safety.

What is reasonably well-established:

• Short-term safety (weeks to months) is good. Common side effects include headache, daytime sleepiness and morning grogginess; serious adverse events are rare.
• Medium-term safety (the 24-month Maras 2018 trial in autistic children) is reasonable, with no signal of concern on growth or pubertal development across that period ^[2].
• Drug interactions are limited but real; fluvoxamine and some other medications affect melatonin metabolism, and the prescriber will consider this.

What is less certain:

• Very long-term effects (multiple years of paediatric use into adolescence and adulthood) are not as well-characterised as the 24-month data. The published evidence is still accumulating.
• The puberty question. Theoretical concern has been raised about whether long-term melatonin in pre-pubertal children could affect timing of puberty, given melatonin's role in the hypothalamic-pituitary-gonadal axis in some animal studies. The Boafo 2019 review of the available human evidence found no clear signal of harm, but the data is limited and the question is not fully settled ^[5]. This is one of the points worth raising with the prescriber for long-term use.
• The optimal dose-response relationship is not fully characterised, particularly across the wide range of doses used historically. UK practice tends to favour the lower end of the dose range, and the prescriber will guide the specific choice.

The general clinical position: melatonin is a useful tool, with reasonable short-to-medium-term evidence, used as part of a wider approach. The very long-term unknowns are real but not currently considered to outweigh the benefit in children with significant sleep difficulty that has not responded to non-pharmacological approaches.

When melatonin fits and when it does not

Melatonin fits well when:

• Behavioural and environmental measures have been genuinely tried for several weeks (see paediatric sleep in autism for the environmental detail).
• The child has significant sleep onset insomnia or a delayed sleep phase pattern.
• The child is autistic (where Slenyto is licensed) or has another neurodevelopmental picture where off-label use has reasonable evidence.
• The sleep difficulty is materially affecting daytime function (school, family life, the child's wellbeing).

Melatonin fits less well when:

• Behavioural and environmental work has not been tried (in most cases this should come first).
• The primary sleep issue is sleep maintenance (frequent night waking) rather than sleep onset; immediate-release melatonin does little for this, and even prolonged-release helps less than for onset.
• The picture suggests an underlying sleep disorder that needs specific treatment (sleep apnoea, restless legs, parasomnias).
• The expectation is that melatonin will fix the problem on its own.

What to ask your GP or paediatrician

A short list of useful questions:

• Have we tried the environmental and behavioural measures thoroughly enough for melatonin to be appropriate now?
• Is Slenyto appropriate (for autistic children) or is off-label immediate-release melatonin more appropriate for our specific picture?
• What dose are you starting at, and what is the plan for adjustment?
• What is the plan for review (typically four to eight weeks)?
• What are the specific things to watch for in terms of side effects?
• How long do you anticipate my child being on it?

What this means in practice

• In the UK, melatonin is prescription-only, not over-the-counter as in the US. The conversation runs through the GP or paediatrician.
• Slenyto is licensed in the UK for autistic children and adolescents (and Smith-Magenis syndrome) aged 2 to 18 where sleep hygiene measures have been insufficient.
• Off-label paediatric melatonin is common and supported by clinical evidence in ADHD, delayed sleep phase, and other neurodevelopmental contexts.
• Safety evidence is reasonable to 24 months (Maras 2018); very long-term data is still accumulating. The puberty question has theoretical basis but no clear human signal of harm to date.
• Melatonin works best alongside environmental and behavioural sleep work, not instead of it.

When to speak to a professional

Speak to your GP or paediatrician if you have tried behavioural and environmental sleep work thoroughly and the picture has not shifted, particularly if your child is autistic (where Slenyto is licensed) or has another neurodevelopmental picture. For NHS routes specifically, your child's existing paediatric team is usually the right first call. NeuroFX child ADHD assessment and child autism assessment services can address melatonin for patients in our paediatric service where clinically appropriate. SleepFX (our sister product) offers structured paediatric sleep programmes for neurodivergent children alongside or in advance of any medication conversation.

Sources

1. British National Formulary for Children (BNFc). https://bnfc.nice.org.uk/
2. Maras A, Schroder CM, Malow BA, et al. Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology. 2018;28(10):699-710.
3. Bruni O, Angriman M, Calisti F, et al. Practitioner review: treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities. Journal of Child Psychology and Psychiatry. 2018;59(5):489-508.
4. Goldman SE, Adkins KW, Calcutt MW, et al. Melatonin in children with autism spectrum disorders: endogenous and pharmacokinetic profiles. Journal of Autism and Developmental Disorders. 2014;44(10):2525-2535.
5. Boafo A, Greenham S, Alenezi S, et al. Could long-term administration of melatonin to prepubertal children affect timing of puberty? Sleep Medicine. 2019;55:148-155.
6. MHRA. Melatonin prescribing guidance. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
7. NICE. Slenyto prolonged-release tablets for treating insomnia in children with autism spectrum disorder or Smith-Magenis syndrome. https://www.nice.org.uk/